Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological disorders. Co.'s product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action, specifically designed to increase histamine signaling in the brain by binding to H3 receptors. WAKIX is used for the treatment of excessive daytime sleepiness (EDS), in adult patients with narcolepsy, focusing on the treatment of EDS associated with Prader-Willi Syndrome and myotonic dystrophy. Co. is also exploring pitolisant for treatments in other rare neurological disorders affected by fatigue and cognitive impairments. The HRMY stock yearly return is shown above.
The yearly return on the HRMY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HRMY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|